Archives
-
MK-8745: Aurora A Biology to Translational Evidence
2026-09-28
MK-8745 provides a practical way to test whether elevated Aurora A is merely a tumor feature or a functional dependency. By connecting mitotic arrest, genotype-aware apoptosis, retinoblastoma pathology, lymphoma models, and xenograft response, researchers can build a more decision-ready translational evidence package.
-
Palonosetron in Chemotherapy-Induced Nausea Prevention
2026-09-28
Ruhlmann and Herrstedt review palonosetron’s distinctive 5-HT3-receptor pharmacology and the clinical evidence for preventing chemotherapy-induced nausea and vomiting (CINV), with particular attention to delayed symptoms. Their central message is that pharmacologic differences matter only when they translate into meaningful clinical outcomes, and that palonosetron should be assessed within combination antiemetic regimens and across separate acute and delayed windows.
-
Firefly Luciferase mRNA: Workflow & LNP Insights
2026-09-27
Build a sensitive, interpretable luciferase readout with Cap1-capped, 5-moUTP modified mRNA—and separate delivery performance from cell health and assay chemistry. A recent cryogenic mass-spectrometry study adds a useful LNP design perspective, while a practical pilot workflow helps researchers optimize transfection without treating one dose as universal.
-
β-Galactosidase Reporter Assay Kit for Promoter Studies
2026-09-26
A β-galactosidase reporter assay can turn promoter activity into a measurable enzyme readout, but the signal reflects more than transcription alone. This guide connects assay design and interpretation to new work on modular promoters that function in both Escherichia coli and Saccharomyces cerevisiae.
-
JC-1 Assay in Cancer Immunomodulation
2026-09-25
Explore how a mitochondrial membrane potential assay can sharpen interpretation of cancer immunomodulator studies. This article connects JC-1 readouts with recent TrxR/MAPK findings while clarifying what mitochondrial depolarization can—and cannot—prove.
-
Rhamnolipid LNPs Target Dendritic Cells in mRNA Vaccines
2026-09-25
This study replaces PEG-lipids in mRNA lipid nanoparticles with microbial rhamnolipids, combining particle stabilization with immune stimulation. The resulting particles showed dendritic-cell-associated uptake, lymph-node-directed expression, and stronger vaccine responses than size-matched PEG-LNPs, while avoiding a reported PEG-associated mast-cell response during repeat dosing.
-
HCMV UL38 Destabilizes IRS1 to Attenuate AKT
2026-09-24
The study links the HCMV protein UL38 to reduced serum responsiveness of AKT, identifying mTORC1-dependent IRS1 destabilization as the proposed mechanism. Its combination of viral loss-of-function, UL38 expression, and pathway-inhibition experiments supports a cell-intrinsic feedback model, while leaving questions about mechanism and relevance across infection settings for future work.
-
DOTAP Workflows for Functional Genomics
2026-09-24
Use DOTAP to build a tunable starting point for plasmid, RNA, and oligonucleotide delivery—then optimize the lipid-to-cargo ratio for your cell model instead of assuming one formulation fits all. A recent immunometabolism study offers a useful design lesson about targeted delivery, while not testing DOTAP itself.
-
Measuring Ferroptosis Beyond a Single Viability Number
2026-09-23
A ferroptosis experiment can show a compelling mechanistic story and still leave a central question unanswered: did the treatment reduce viable cells? This article connects recent findings on ciprofloxacin–RSL3 responses to practical ATP-based cell viability measurement, explaining where luminescence adds value, where it can mislead, and how to build stronger translational evidence.
-
AP20187 for Conditional Cell Signaling
2026-09-23
AP20187 is a chemical inducer of dimerization for temporally controlled fusion-protein signaling, reporter activation, regulated cell therapy, and metabolic research. This workflow-focused guide also shows how to adapt the platform to stromal–immune assays inspired by senescent CAF research without overstating what the reference study demonstrated.
-
Cas9 mRNA Precision: The Export Layer
2026-09-22
Precision genome editing is not determined by nuclease chemistry alone. This thought-leadership analysis connects Cap1 and m1Ψ mRNA design with the emerging role of Cas9 mRNA nuclear export, translating mechanistic evidence into practical guidance for researchers developing reproducible genome editing workflows.
-
Biological Sex in Mouse mRNA Vaccine Studies
2026-09-22
Binici and colleagues examined whether biological sex alters reporter expression and immune responses after intramuscular administration of mRNA-loaded lipid nanoparticles in mice. Female BALB/c mice produced stronger total IgG responses than males, whereas local luciferase expression did not differ significantly, highlighting the need to treat sex as an explicit variable in preclinical mRNA vaccine design.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-09-21
Build a dual-readout workflow that separates mRNA uptake from productive translation. EZ Cap Cy5 Firefly Luciferase mRNA combines Cy5 tracking with luciferase bioluminescence to optimize delivery systems, intracellular trafficking, and translational performance.
-
PTC124 (Ataluren) and Lowe Syndrome Models
2026-09-21
PTC124 (Ataluren) is a small molecule investigated for readthrough of selected premature stop codons. Lowe syndrome models in the cited study support OCRL gene augmentation and CRISPR correction, but they do not establish ataluren as a treatment for OCRL deficiency.
-
D-Luciferin (potassium salt) for Reliable BLI
2026-09-20
D-Luciferin (potassium salt), SKU C3654, supports controlled firefly luciferase workflows from in vitro reporter assays to in vivo bioluminescence imaging. This scenario-based guide explains formulation compatibility, storage, experimental controls, data interpretation, and practical vendor-selection criteria.